Brain tumor drug delivered directly via pump shows promise in early trial
NCT ID NCT06666712
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This early-stage study tests a method called convection-enhanced delivery (CED) to give the chemotherapy drug topotecan directly to recurrent brain tumors in people with a specific genetic mutation (IDH-mutant malignant glioma). A pump placed under the skin delivers the drug through a thin tube to the tumor over several weeks. The main goal is to check safety, and the study also looks at how well the drug reaches the tumor and whether it slows tumor growth. Only 6 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR, RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital
RECRUITINGNew York, New York, 10032, United States
Contact
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.